Ongoing Clinical Trials for Supraventricular Arrhythmia
There are currently 2 clinical trials investigating new treatments for supraventricular arrhythmia, specifically focusing on atrial fibrillation and related rhythm disorders. These studies are being conducted in the Netherlands and France, testing medications that may help restore normal heart rhythm or prevent irregular heartbeats after certain heart procedures.
Clinical trial locations
- France
- Netherlands
Study on Semaglutide for Achieving Sinus Rhythm in Patients with Obesity and Persistent Atrial Fibrillation
This trial is investigating whether Semaglutide, a medication currently used for weight management, can help restore normal heart rhythm in patients who have both obesity and persistent atrial fibrillation. The study is being conducted in the Netherlands and will follow participants for one year.
Who can participate:
- Adults aged 18 years or older
- People with symptomatic, first detected persistent atrial fibrillation that was noticed for the first time within the past 6 months
- Individuals with obesity (BMI of 30 or higher), or those with a BMI of 27 or higher who also have weight-related health issues such as high blood pressure, high cholesterol, sleep problems, or heart disease
- Patients scheduled for electrical cardioversion, a procedure to help restore normal heart rhythm
- Those willing to provide written informed consent
Who cannot participate:
- People without obesity
- Those who do not have atrial fibrillation or symptomatic persistent atrial fibrillation
- Individuals outside the specified age range
- Members of vulnerable populations who may need special protection or care
What the trial involves: The main goal is to determine if Semaglutide can help patients achieve a normal heart rhythm (sinus rhythm) after one year of treatment. Participants will receive either Semaglutide or a placebo through a weekly injection under the skin. Throughout the study, researchers will monitor various health parameters, including symptoms related to atrial fibrillation, quality of life, weight changes, blood pressure, and cholesterol levels. The study will also track hospital visits and any changes in overall health indicators.
Investigational drug: Semaglutide is a medication that mimics a hormone called GLP-1, which helps regulate appetite and insulin levels. It is given once a week through an injection under the skin at a dose of 2.4 mg. The medication is being tested to see if weight loss and metabolic improvements can help restore normal heart rhythm in patients with atrial fibrillation and obesity.
Study on Flecainide to Reduce Risk of Atrial Arrhythmia After Patent Foramen Ovale Closure in Patients
This trial is examining whether Flecainide, a heart rhythm medication, can prevent irregular heartbeats in patients who have undergone a procedure to close a Patent Foramen Ovale (PFO)—a small opening in the heart that didn’t close naturally after birth. The study is taking place in France and focuses on the first three months following the closure procedure.
Who can participate:
- Adults aged 18 years or older
- Patients who are candidates for PFO closure, as confirmed by a multidisciplinary team of medical experts
- Individuals affiliated with Social Security
- Those who have provided signed written consent
- Patients who have had successful PFO closure without major complications
Who cannot participate:
- People with a history of atrial arrhythmia (irregular heartbeat) or tachycardia (fast heartbeat)
- Individuals who have already undergone PFO closure before this study
- Those outside the specified age range
- Members of vulnerable populations
What the trial involves: The main purpose is to determine if Flecainide can prevent atrial arrhythmia during the three months following PFO closure. After the closure procedure, participants will have a small device called an Insertable Cardiac Monitor (ICM) implanted to track heart activity continuously. Participants will then be randomly assigned to receive either Flecainide or another treatment. The study will monitor for episodes of irregular heartbeats lasting 30 seconds or more, including atrial fibrillation, atrial flutter, or atrial tachycardia. Researchers will also track palpitations, strokes, unexpected medical visits, and any side effects related to the medication over a six-month period.
Investigational drug: Flecainide is an antiarrhythmic medication taken orally in tablet form. It works by blocking sodium channels in the heart, which helps stabilize heart rhythm. The trial is testing whether taking Flecainide for three months after PFO closure can reduce the risk of developing irregular heartbeats. Flecainide is classified as a Class IC antiarrhythmic agent and is well-established in medical literature for managing heart rhythm disorders.
Summary
These two clinical trials represent different approaches to managing supraventricular arrhythmia, particularly atrial fibrillation. The first trial explores an innovative connection between weight management and heart rhythm by testing whether Semaglutide can help restore normal rhythm in patients with both obesity and atrial fibrillation. This represents a novel approach that addresses underlying metabolic factors that may contribute to irregular heartbeats.
The second trial takes a more traditional preventive approach by testing whether Flecainide can prevent irregular heartbeats from developing after a heart procedure. This study is particularly important for patients undergoing PFO closure, as it aims to reduce complications that can occur after this intervention.
Geographically, these trials are distributed across Western Europe, with one study in the Netherlands and one in France. Both studies use careful monitoring techniques—one through regular assessments over a year, and the other using an implantable cardiac monitor for continuous heart rhythm tracking. The different patient populations and treatment approaches in these trials reflect the diverse nature of supraventricular arrhythmia and the ongoing search for effective management strategies tailored to specific patient needs.